Literature DB >> 1289337

Acute sterile hemorrhagic cystitis after a single intravenous administration of cyclophosphamide in three dogs.

J L Peterson1, C G Couto, A S Hammer, R D Ayl.   

Abstract

Three dogs receiving cyclophosphamide IV as part of a combination chemotherapeutic regimen developed macrohematuria, stranguria, and pollakiuria within 24 hours of administration of the first dose of this drug. An 11-year-old spayed mixed-breed dog with an oral squamous cell carcinoma was administered 250 mg of cyclophosphamide/m2 of body surface, whereas a 4-year-old castrated male Gordon Setter was treated with 100 mg of cyclophosphamide/m2 and a 6-year-old male German Shepherd Dog with a cutaneous hemangiosarcoma was administered 140 mg of cyclophosphamide/m2. Aerobic bacterial culture, antimicrobial susceptibility testing, and urinalysis were performed on urine obtained by cystocentesis from all 3 dogs after hematuria was observed. Sterile hemorrhagic cystitis was diagnosed on the basis of large numbers of RBC in the urine, lack of pathogens on bacterial culturing of urine, and clinical signs. Although cyclophosphamide-induced cystitis in dogs has been reported in the literature numerous times, acute episodes developing within 24 hours of administration of the first dose have not been reported in this species with the use of therapeutic doses. Therefore, appropriate precautionary steps should be taken, even when the drug is being administered intermittently.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1289337

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  2 in total

1.  Pharmacokinetics of cyclophosphamide after oral and intravenous administration to dogs with lymphoma.

Authors:  E Warry; R J Hansen; D L Gustafson; S E Lana
Journal:  J Vet Intern Med       Date:  2011-05-12       Impact factor: 3.333

2.  Doxorubicin and cyclophosphamide for the treatment of canine lymphoma: a randomized, placebo-controlled study.

Authors:  J C Lori; T J Stein; D H Thamm
Journal:  Vet Comp Oncol       Date:  2010-09       Impact factor: 2.613

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.